AstraZeneca Says Danicopan Met Primary Endpoint in Phase 3 Trial
16 September 2022 - 8:53AM
Dow Jones News
By Kyle Morris
AstraZeneca PLC said Friday that its danicopan add-on to
Ultomiris or Soliris met its primary endpoint in a Phase 3 trial
for patients with paroxysmal nocturnal haemoglobinuria who
experience clinically significant extravascular haemolysis.
The Anglo-Swedish pharma giant said the ALPHA Phase 3 trial
showed positive high-level results, meeting its primary endpoint of
a change in haemoglobin from baseline at 12 weeks and key secondary
endpoints
Paroxysmal nocturnal haemoglobinuria is a rare blood disorder
that destroys red and white blood cells and can cause thrombosis,
among other things, resulting in and result in organ damage and
potentially death.
Write to Kyle Morris at kyle.morris@dowjones.com
(END) Dow Jones Newswires
September 16, 2022 02:38 ET (06:38 GMT)
Copyright (c) 2022 Dow Jones & Company, Inc.
AstraZeneca (NASDAQ:AZN)
Historical Stock Chart
Von Jun 2024 bis Jul 2024
AstraZeneca (NASDAQ:AZN)
Historical Stock Chart
Von Jul 2023 bis Jul 2024
